Tumour marker development: Towards validation of clinically useful markers

European Journal of Cancer, Supplement

Volumn 5, Issue 5, 2007, Pages 77-81

  Hayes, Daniel F ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE MARKER; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REPRODUCIBILITY; RISK ASSESSMENT; VALIDATION STUDY;

EID: 35548932486     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(07)70026-5     Document Type: Article

References (17)

1. ASCO Expert Panel. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer: Report of the American Society of Clinical Oncology Expert Panel. J Clin Oncol 14 (1996) 2843-2877
2. ASCO Expert Panel. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 16 (1998) 793-795
3. Bast Jr. R., Ravdin P., Hayes D., et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 (2001) 1865-1878
4. Bast Jr. R., Ravdin P., Hayes D., et al. Errata: 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 (2001) 4185-4188
5. Henry N., and Hayes D. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist 11 (2006) 541-552
6. Hayes D., Bast R., Desch C., et al. A tumor marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88 (1996) 1456-1466
7. McGuire W. Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 83 (1991) 154-155
8. Simon R., and Altman D. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69 (1994) 979-985
9. McShane L., Altman D., Sauerbrei W., et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97 (2005) 1180-1218
10. McShane L., Altman D., Sauerbrei W., et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23 (2005) 9067-9072
11. McShane L., Altman D., Sauerbrei W., et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93 (2005) 387-391
12. Ravdin P., Siminoff L., Davis G., et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19 (2001) 980-991
13. Ransohoff D. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4 (2004) 309-314
14. Ransohoff D. Cancer. Developing molecular biomarkers for cancer. Science 299 (2003) 1679-1680
15. Coates A., and Simes R. Patient Assessment of Adjuvant Treatment in Operable Breast Cancer (1992), John Wiley & Sons Ltd, New York, NY
16. Ravdin P., Siminoff I., and Harvey J. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 16 (1998) 515-521
17. Lindley C., Vasa S., Sawyer T., et al. Quality of life and preferences for treatment following systemic adjuvant therapy for early stage breast cancer. J Clin Oncol 16 (1998) 1380-1387